Screener
Celldex Therapeutics CLDX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's EBITDA?
- Celldex Therapeutics (CLDX) reported EBITDA of -$79.72M in Q2 2026.
- How has Celldex Therapeutics's EBITDA changed year-over-year?
- Celldex Therapeutics's EBITDA decreased by 26.6% year-over-year, from -$62.98M to -$79.72M.
- What is the long-term trend for Celldex Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Celldex Therapeutics's EBITDA has grown at a 42.9% compound annual growth rate (CAGR), from -$68.18M to -$283.99M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Celldex Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude